Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03554408 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
A Phase 1 study of Human Immunodeficiency Virus, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT03554408: Completed Phase 1 study of Human Immunodeficiency Virus, sponsored by Rockefeller University.
NCT03554408 is a Phase 1 study of Human Immunodeficiency Virus that has completed, run by Rockefeller University. The registered enrollment target is 77 participants, below the 182-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03554408, a Phase 1 study of Human Immunodeficiency Virus, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.
Primary Outcome
Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events.
Conditions Studied
Interventions
- DRUG 3BNC117-LS
- DRUG 10-1074-LS
Study Locations (1)
New York
- The Rockefeller University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2021-02-04 |
| Phase | Phase 1 |
What the finished NCT03554408 record still lists
NCT03554408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 182-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which 3BNC117-LS is the first listed.
NCT03554408 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03554408 about?
NCT03554408 is a clinical study titled "First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS". This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.
What is the current status of trial NCT03554408?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2018-06-20. Estimated completion is 2021-02-04.
What conditions does trial NCT03554408 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT03554408?
The interventions under investigation include: 3BNC117-LS (DRUG), 10-1074-LS (DRUG).
Who is sponsoring clinical trial NCT03554408?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03554408 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03554408's enrollment target sits among peer trials
77 20th of 39 higher than 20 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
RECRUITING · Phase 1
-
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
COMPLETED · Phase 1
-
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
COMPLETED · Phase 1
-
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
COMPLETED · Phase 1
-
First in Human Study of TLC-ART 101 (ACTU 2001)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI